.Merck beats profits requirements, increases purchases expectation on tough need for best drugs like Keytruda CNBCMerck & Co. (MRK United States) Trumps Revenue Estimates as Keytruda Purchases Rise BloombergMerck Stock: Pharma Titan Posts Sturdy Outcomes, But Outlook Drops Short Capitalist's Service DailyMerck Announces Second-Quarter 2024 Financial Results Yahoo FinanceMerck trumps earnings as well as sales desires amidst Keytruda strong point, yet delivers blended full-year expectation MarketWatch.